Skip to content
OpenCapital
Get started

Repligen RGEN Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
Charles River Laboratories logo
Charles River LaboratoriesCRL
——

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's share-based compensation expense related to employee stock plans?
Repligen (RGEN) reported share-based compensation expense related to employee stock plans of $8.32M in Q1 2026.
How has Repligen's share-based compensation expense related to employee stock plans changed year-over-year?
Repligen's share-based compensation expense related to employee stock plans increased by 14.4% year-over-year, from $7.27M to $8.32M.
What is the long-term trend for Repligen's share-based compensation expense related to employee stock plans?
Over 2 years (2021 to 2023), Repligen's share-based compensation expense related to employee stock plans has grown at a -3.6% compound annual growth rate (CAGR), from $27.5M to $25.58M.